Numab Therapeutics
Last verified 2026-06-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $220.0Mattributed |
|---|---|
| Latest round | series-c, $60.5M, 2025-01-01attributed |
| Founded | 2011 |
| Headquarters | Horgen, Switzerland |
| Industry | bio |
| Stage | series-b+ |
| Website | numab.com |
Biotech developing multi-specific antibody therapeutics for cancer immunotherapy and inflammatory diseases
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | series-c | $60.5M | undisclosed |
Detected tech stack
apache, apache http server, constant contact, jquery, modernizr, mysql, php, underscore.js, wordpress
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $60.5M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $220.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | numab.com, read 2026-06-07 |
| Description | self-reported | numab.com, read 2026-06-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.